GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis
Sign Up to like & getrecommendations! Published in 2017 at "BMJ Case Reports"
DOI: 10.1136/bcr-2017-221078
Abstract: Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC). Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase… read more here.
Keywords: inhibitor; two patients; gsk2586184; jak1 selective ... See more keywords